TerminatedPhase 2NCT00005997
Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer
Studying Adenocarcinoma of the gallbladder and extrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Case Comprehensive Cancer Center
- Principal Investigator
- Afshin Dowlati, MDIreland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
- Intervention
- becatecarin(drug)
- Enrollment
- 72 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 1999 – 2005
Study locations (3)
- Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States
- Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
- Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00005997 on ClinicalTrials.govOther trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07265674A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract CancerJ-Pharma Co., Ltd.
- RECRUITINGPHASE3NCT06282575Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerJazz Pharmaceuticals
- RECRUITINGNCT07007832Bile Omics for Diagnosing Indeterminate Biliary StricturesShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- ACTIVE NOT RECRUITINGPHASE1NCT03257761Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder CancerUniversity of Southern California
See all trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract →